GILEAD SCIENCES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GILEAD SCIENCES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $7.42B | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $6.58B | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $5.14B | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $5.55B | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $5.88B | Feb 25, 2021 |
| FY2020 | Sep 30, 2019 | $5.60B | Feb 25, 2021 |
| FY2020 | Jun 30, 2019 | $5.69B | Feb 25, 2021 |
| FY2020 | Mar 31, 2019 | $5.28B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $5.80B | Feb 25, 2020 |
| FY2019 | Sep 30, 2018 | $5.60B | Feb 25, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.44B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $28.75B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $27.12B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $27.28B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $27.31B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $24.69B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $22.45B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $22.13B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $26.11B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $30.39B | Feb 26, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $5.95B | Feb 27, 2018 |
| FY2017 | Sep 30, 2017 | $6.51B | Feb 27, 2018 |
| FY2017 | Jun 30, 2017 | $7.14B | Feb 27, 2018 |
| FY2017 | Mar 31, 2017 | $6.51B | Feb 27, 2018 |
| FY2017 | Dec 31, 2016 | $7.32B | Feb 27, 2018 |
| FY2017 | Sep 30, 2016 | $7.50B | Feb 27, 2018 |
| FY2017 | Jun 30, 2016 | $7.78B | Feb 27, 2018 |
| FY2017 | Mar 31, 2016 | $7.79B | Feb 27, 2018 |
| FY2016 | Dec 31, 2015 | $8.51B | Feb 27, 2017 |
| FY2016 | Sep 30, 2015 | $8.30B | Feb 27, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $5.93B | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $5.35B | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $4.00B | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $4.50B | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $4.11B | Feb 25, 2021 |
| FY2020 | Sep 30, 2019 | $4.48B | Feb 25, 2021 |
| FY2020 | Jun 30, 2019 | $4.61B | Feb 25, 2021 |
| FY2020 | Mar 31, 2019 | $4.24B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $4.11B | Feb 25, 2020 |
| FY2019 | Sep 30, 2018 | $4.37B | Feb 25, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.51B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $480.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $5.67B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $4.59B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $6.23B | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | $1.55B | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $360.00M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | ($3.34B) | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $1.55B | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $2.70B | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.02B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.66B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $7.61B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $7.33B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $9.92B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $4.07B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $4.29B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $8.20B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $14.12B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $17.63B | Feb 26, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $9.11B | Feb 25, 2020 |
| FY2019 | Dec 31, 2018 | $5.02B | Feb 25, 2020 |
| FY2019 | Dec 31, 2017 | $3.73B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $5.10B | Feb 26, 2019 |
| FY2017 | Dec 31, 2015 | $3.01B | Feb 27, 2018 |
| FY2016 | Dec 31, 2014 | $2.85B | Feb 27, 2017 |
| FY2015 | Dec 31, 2013 | $2.12B | Feb 24, 2016 |
| FY2014 | Dec 31, 2012 | $1.76B | Feb 25, 2015 |
| FY2013 | Dec 31, 2011 | $1.23B | Feb 25, 2014 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.77B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $6.09B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $6.09B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $5.67B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $5.25B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $5.15B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $4.38B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $4.06B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $3.88B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $3.40B | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.02B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $10.83B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $8.01B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $9.07B | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $11.38B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $8.17B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $9.14B | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $8.40B | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $11.90B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $17.05B | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $563.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $523.00M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $585.00M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $728.00M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $579.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $650.00M | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $825.00M | Feb 23, 2022 |
| FY2020 | Dec 31, 2018 | $924.00M | Feb 25, 2021 |
| FY2013 | Dec 31, 2013 | $134.00M | Feb 25, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.02B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $59.00B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $62.13B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $63.17B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $67.95B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $68.41B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $61.63B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $63.68B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $70.28B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $56.98B | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.70B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $19.33B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $22.83B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $21.24B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $21.07B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $18.20B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $22.53B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $21.39B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $20.44B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $18.89B | Feb 27, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.31B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $8.31B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $8.31B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $8.31B | Feb 23, 2024 |
| FY2023 | Dec 31, 2021 | $8.33B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $8.11B | Feb 22, 2023 |
| FY2021 | Dec 31, 2019 | $4.12B | Feb 23, 2022 |
| FY2019 | Dec 31, 2018 | $4.12B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $4.16B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $1.17B | Feb 27, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.73B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $11.50B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $16.30B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $15.69B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $16.32B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $14.38B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $19.39B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $19.02B | Feb 25, 2020 |
| FY2018 | Jan 1, 2018 | $19.20B | Feb 26, 2019 |
| FY2018 | Dec 31, 2017 | $19.01B | Feb 26, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $5.41B | Feb 22, 2023 |
| FY2022 | Dec 31, 2021 | $5.34B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $6.00B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | $11.63B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $17.94B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $7.59B | Feb 26, 2019 |
| FY2018 | Dec 31, 2016 | $8.23B | Feb 26, 2019 |
| FY2018 | Dec 31, 2015 | $12.85B | Feb 26, 2019 |
| FY2017 | Dec 31, 2014 | $10.03B | Feb 27, 2018 |
| FY2016 | Dec 31, 2013 | $2.11B | Feb 27, 2017 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.94B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $26.71B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $24.99B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $25.23B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $26.70B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | $31.40B | Feb 23, 2022 |
| FY2015 | Dec 31, 2015 | $22.18B | Feb 24, 2016 |
| FY2015 | Dec 31, 2014 | $12.40B | Feb 24, 2016 |
| FY2014 | Dec 31, 2013 | $6.64B | Feb 25, 2015 |
| FY2013 | Dec 31, 2012 | $8.22B | Feb 25, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 4 | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | (2) | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 2 | Feb 25, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | 4 | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | (2) | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | 2 | Feb 25, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.24B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 1.25B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 1.25B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 1.25B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | 1.25B | Feb 22, 2023 |
| FY2021 | Dec 31, 2020 | 1.25B | Feb 23, 2022 |
| FY2020 | Dec 31, 2019 | 1.27B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 1.28B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 1.31B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 1.31B | Feb 27, 2018 |